CSDX 8-K
Cs Diagnostics Corp. (CSDX)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (earliest reported
date):
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification Number) |
(Address of Principal Executive Offices) (Zip Code)
+
Registrant's telephone number, including area code
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act: None
| Title of each Class | Trading Symbol | Name of each exchange on which registered |
| N/A | FZRO | OTC Market Group |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter)
Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
ITEM 8.01 - OTHER EVENTS
CS Diagnostics Corp, a renowned member of the CS Group and medical distribution company dedicated to improving patient care through innovative solutions. By working closely with trusted global healthcare partners, experienced professionals and top universities CS Diagnostics Corp. is focused on prevention, improving therapy results by being safer and causing less side effects. One of such products is the CS Protect Hydrogel. This novel spacer gel has been specially developed to separate healthy from malignant tissues during Radiation therapy, thereby significantly improving the chances of recovery for prostate cancer patients, for example. Increasing the effectiveness and safety of the therapy is giving patients much more comfort and Quality of life.
Future products are only included in the CS Diagnostics Corp. portfolio after being intensively tested to the highest standards.
CS Diagnostics Corp. serves a diverse international market and is well experienced in carrying out complicated regulatory procedures to achieve product approvals and Marketing authorizations. Its global presence strengthens strategic collaborations with healthcare providers around the world, ensuring that its comprehensive services and solutions are available in multiple countries. With a focus on quality and a broad range of solutions, CS Diagnostics Corp. is well positioned to transform the future of healthcare by delivering on the promise of better health and vitality through better technology.
Company Officers & Contacts
Thomas Fahrhoefer, President
Thomas Josef Migotsch, Vice President, COO
Mohammad EsSayed, Vice President, CFO
Janel Luzana, Company Secretary
Mahmoud A. Al-Sayyed, Independent Director
Lauren Kate Ugur, Independent Director
| 2 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized.
| CS DIAGNOSTICS CORP. | |
| /s/ Mohammad EsSayed | |
| Mohammad EsSayed | |
| Title: Chief Financial Officer | |
| Dated: October 3, 2024 |
| 3 |